NewsDialy
The annual international BIO conference in San Diego brought biotech and startup executives face-to-face with two forces reshaping the global drug industry: China's deepening capabilities in drug development and the early competitive signals emerging from artificial intelligence.
The week-long gathering at the San Diego convention made clear that U.S.-centric biotech sees both Washington policy and AI adoption as the levers most immediately within reach.
China's Growing Power in Drug Development Takes Center Stage China's expanding role in the business of developing new drugs became one of the central concerns of BIO 2026, discussed both on stage and in conversations across the exhibition floor.
The topic carried urgency because drug development has historically been a domain where U.S.
Keep reading